Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00228969 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

A Phase 2 study of Refractory Epilepsy, sponsored by SK Life Science.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00228969 is a Phase 2 study of Refractory Epilepsy that has completed, run by SK Life Science. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00228969, a Phase 2 study of Refractory Epilepsy, has completed, sponsored by SK Life Science.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive

Conditions Studied

Refractory Epilepsy

Interventions

  • DRUG RWJ-333369

Study Locations (20)

Alabama

  • - Birmingham
  • - Huntsville
  • - Mobile
  • - Northport

California

  • - Irvine
  • - Northridge
  • - Sacramento

Kentucky

  • - Lexington
  • - Louisville

Minnesota

  • - Golden Valley
  • - Saint Paul

Arizona

  • - Phoenix

Arkansas

  • - Little Rock

Colorado

  • - Fort Collins

Delaware

  • - Wilmington

Trial Details

FieldValue
Start Date 2005-02
Est. Completion 2006-05
Phase Phase 2

Sponsor

SK Life Science

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00228969

The ClinicalTrials.gov registry entry for NCT00228969 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Refractory Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which RWJ-333369 is the first listed.

NCT00228969 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Alabama, California, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00228969 about?

NCT00228969 is a clinical study titled "Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy". The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive

What is the current status of trial NCT00228969?

This trial is currently completed. It is a Phase 2 study. The study started on 2005-02. Estimated completion is 2006-05.

What conditions does trial NCT00228969 study?

This clinical trial studies the following conditions: Refractory Epilepsy.

What interventions are being tested in trial NCT00228969?

The interventions under investigation include: RWJ-333369 (DRUG).

Who is sponsoring clinical trial NCT00228969?

This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00228969 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Epilepsy

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.